The Researched Abuse Diversion and Addiction-Related Surveillance (RADARS^®) System was developed by Purdue Pharma L.P. in 2001 as a way to address the risk management obligations, specifically the challenges they faced with reports of abuse, misuse and diversion of their product, OxyContin^®.

In 2006, the RADARS System was acquired by Denver Health and Hospital Authority (DHHA) and became an independent, nonprofit operation of the Rocky Mountain Poison and Drug Center (RMPDC), a division of DHHA.

Organization

The Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS®) System is a prescription drug abuse, misuse and diversion surveillance system that collects timely product-and geographically-specific data. The RADARS System measures rates of abuse, misuse and diversion throughout the United States, contributing to the understanding of trends and aiding the development of effective interventions. These data assist pharmaceutical companies in fulfillment of their regulatory obligations such as risk evaluation and mitigation strategies (REMS).